Garetosmab ( DrugBank: Garetosmab )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
272進行性骨化性線維異形成症2

272. 進行性骨化性線維異形成症


臨床試験数 : 39 薬物数 : 38 - (DrugBank : 7) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 95
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05394116
(ClinicalTrials.gov)
November 21, 20224/5/2022The Examination of Safety and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans ProgressivaFibrodysplasia Ossificans ProgressivaDrug: Garetosmab;Drug: PlaceboRegeneron PharmaceuticalsNULLRecruiting18 YearsN/AAll66Phase 3Japan;Poland;Spain;United Kingdom
2NCT04577820
(ClinicalTrials.gov)
October 13, 202130/9/2020Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)Evaluation of Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans ProgressivaFibrodyplasia Ossificans Progressiva (FOP);Heterotopic Ossification (HO)Drug: garetosmabRegeneron PharmaceuticalsNULLWithdrawn18 Years60 YearsAll0Phase 3NULL